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Abstract
Objective—To assess the role of amitriptyline in the effectiveness of an outpatient protocol for 
weaning medically complicated children from tube to oral feeding.
Study design—Twenty-one children seen in multidisciplinary outpatient feeding teams across 
four sites were recruited to a randomized placebo-controlled trial of a six-month outpatient 
treatment protocol with behavioral, oral-motor, nutrition and medication components.
Results—All of the children who completed the six-month program (73%) were weaned to 
receive only oral feeding, regardless of group assignment. The transition from tube to oral feeding 
resulted in decreases in BMI percentile and pain, some improvements in quality of life, and no 
statistically significant changes in cost.
Conclusions—Amitriptyline is not a key component of this otherwise effective outpatient, 
interdisciplinary protocol for weaning children from tube to oral feeding.
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Feeding problems that require medical intervention occur in 3–10% of children (1). 
Premature infants are overrepresented among children with feeding problems (2). Improved 
preterm infant survival has increased the prevalence of feeding problems in older infants and 
toddlers (3). In addition, severe feeding problems occur in 40–70% of children with chronic 
medical conditions (4,5). Neonates with long intensive care hospitalizations may miss early 
eating learning opportunities and may associate eating with pain or discomfort (6). Gastric 
(G-) and gastrojejunal (G–J) tube feeding requirements may persist for months or years 
secondary to these early medical issues resulting in chronic oral food refusal. As the 
prevalence of gastric tube feeding has increased, so have the challenges associated with 
transitioning a child from tube to oral feeding (7,8).
There are several methods for achieving the transition from tube to oral feeding(9). Many 
programs consist of rigorous behavioral outpatient treatment or inpatient stays (8,10–12). 
Lengthy hospitalization and intensive outpatient treatments cause family disruption, 
emotional distress, and financial burden (13). Few studies, other than case reports (14–16), 
have examined the effectiveness of outpatient feeding programs for transitioning children 
from tube to oral feeding (13). A recent systematic review suggests that appetite 
manipulation and behavioral therapy are efficacious for outpatient tube weaning.(9)
A randomized outpatient study compared 7 weekly outpatient sessions of behavior therapy 
to a traditional nutritional intervention for chronic oral food refusal. The behavioral 
treatment group had a 47% success rate compared with 0% in the nutritional group (13).
An interdisciplinary treatment protocol to transition children from tube to oral feeding was 
developed by our team (17). The initial 9 patients to undergo this multidisciplinary, 
multicomponent treatment all transitioned to oral feeding immediately following treatment, 
and 8 patients (89%) maintained this 6 months after treatment.
Because two medications were involved in the treatment, a randomized controlled trial using 
only one of the medications (amitriptyline) was considered a necessary step to further 
evaluate the role of medication in the patient.
Amitriptyline is used to treat chronic neuropathic pain, cyclic vomiting syndrome, and 
migraine headache in all age groups, except infants and toddlers (18). Currently, there is 
only anecdotal data on the use of amitriptyline in infants and toddlers. At low doses, there 
are no reports of death or serious side effects such as cardiac arrhythmias. Amitriptyline was 
theorized to be a key component of the multidisciplinary treatment protocol.
This study aimed to assess the efficacy of amitriptyline as one component of a 24-week 
outpatient protocol for transitioning children from tube to oral feeding. We hypothesized that 
children receiving amitriptyline would more likely transition to oral feeding (defined as 
consuming at least 90% of their daily calories orally) than those receiving placebo. A 
secondary aim was to assess the role of pain in the efficacy of the protocol. We hypothesized 
that children receiving amitriptyline would demonstrate less pain, as reported by their 
parents/caregivers, and this would contribute to successful transition to oral feeding.
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METHODS
Patients were identified through interdisciplinary feeding teams at each site. Institutional 
Review Board approval (12261) and Clinical Trials.gov registration were obtained prior to 
enrollment. Once a child met the inclusion/exclusion criteria, families were invited to 
participate and consent obtained. Baseline measures were obtained by clinical trials staff at 
each site, after which the statistician assigned the child to placebo/amitriptyline using 
randomization software and conveyed this information to the pharmacy, keeping research 
and clinical staff blind to assignment. Medication and instructions were identical regardless 
of group assignment and included a dose based on subject weight (0.33 mg/kg qhs) (19). 
The dose was increased weekly by 0.33 mg/kg until the final dose equaled 1 mg/kg. Shelf 
life of the active compounded liquid is one month, so refills were provided to both groups 
(placebo/amitriptyline) each month. The amitriptyline and placebo preparation were 
identical for taste, look, and smell. Feeding schedules were changed such that patients were 
fed their usual total volume and usual formula by continuous drip over 12 hours into the 
small intestine. Families were encouraged to contact team members with questions or 
concerns at any time throughout the study. Families who consented to the protocol were 
offered $50 for each major clinical visit (weeks 0, 10 and 24; $150 total) as reimbursement 
for transportation, effort for measure completion, and other costs.
Families received a weekly phone call from a research team member to assess the child’s 
parent-reported weight, feeding habits, progress, and any negative side effects. If serious 
problems arose, providers were unblinded to the group assignment, the subject was 
withdrawn, and patients received all necessary treatment.
Families had 8 outpatient clinic visits after signing consent, each of which took 
approximately one hour (Figure 1). Visits were led by clinical research staff, and measures 
were completed as indicated, as well as medical monitoring at every clinic visit which 
included ECG, vital signs, height, weight, blood draws (CBC w/diff, CMP), and morning 
cortisol (at weeks 10, 15 and 19 only). During the week 10 visit, the team prescribed the 
appetite stimulant megesterol (3mg/kg BID). Five days after beginning the appetite 
stimulant, tube feedings were reduced by 1 hour each night, such that within twelve days 
patients were receiving no calories through their tubes. Megesterol was discontinued after 6 
weeks. Amitriptyline was discontinued 6 months from when it was started by weekly 
titration to smaller doses over 1 month, unless the treating physician decided otherwise 
based upon clinical indicators.
Families were instructed to sit the patient at a table or in a high chair at home for at least 3 
meals daily for approximately 10–20 minutes. Parents were instructed to present a variety of 
foods including some that are preferred, and some that are not, varying textures as 
appropriate for patient skill. Although feeding highly nutritious foods is important, for the 
purpose of switching from tube to oral feedings, the primary focus was on increasing oral 
caloric intake. It was stressed that parents never force anything into their child’s mouth, 
including food.
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Criteria for patient inclusion were 9 months to 9 years of age, having a history of chronic 
oral food refusal (3 months of refusing to eat more than 50% of their caloric required orally) 
and having been tube fed for 3 months or longer. Patients with known gastrointestinal 
disorders which would negatively affect their progress (such as esophageal stricture or 
chronic intestinal pseudo-obstruction) were excluded, as were children with uncontrolled 
seizures or heart disease with cardiac conduction abnormalities. Patients unable to meet the 
behavioral and occupational therapy criteria for necessary oral-motor skills and behavioral 
control (Table I) were excluded or were trained to meet the inclusion criteria and then 
enrolled. Finally, patients were to be withdrawn from the protocol at any time if their weight 
loss exceeded 10% of initial body weight.
Measures
Percentage of kilocalories obtained orally was obtained using the 24 hour food recall, a 
standardized five-pass method developed by the US Department of Agriculture for use in 
national dietary surveillance. This measure has been widely used in several large trials and 
data suggest it is the most valid and reliable method of dietary assessment for children (20). 
The data were collected at week 0, week 10, and week 24 using standardized probes by 
highly trained research staff, and parents were presented with paper food models and 
measuring devices prior to interviews to reference during the recall. Recalls were analyzed 
with the Nutritional Data System for Research, version 2005; University of Minnesota, 
Minneapolis, MN.
Non-communicating Children’s Pain Checklist - Revised (NCCPC-R) is a 30 item measure 
intended to assess pain in children who are unable to speak because of cognitive or physical 
impairments. Previous research indicates strong psychometric properties (a = 0.93) and 
acceptable reliability across 3 time points in the current study (a = 0.80) There are 7 
subscales including vocal, social, facial, activity, body/limbs, physiological, eating/sleeping 
(21). This measure was completed by parents at week 0, week 10, and week 24.
Child quality of life was measured with the Infant Toddler Quality of Life (ITQOL) version 
04.06 questionnaire, which has been validated for children as young as 2 months of age. The 
measure has 97 items which result in 9 multi-item scales, 2 global items, and 2 single item 
(only multi-item scales were included here). The ITQOL is a well-established reliable 
(Crohbach a > .70) and valid measure of infant and toddler QOL. This measure was 
completed by parents at week 0 and week 24.
In order to assess cost of caring for their child, parents completed a simple questionnaire 
asking them the amount of money they spent on the medical care of their child in the 
previous week. Cost were broken out by medications, food, and other care items. This 
measure was completed by parents at week 0 and week 24.
Statistical Analyses
Descriptive statistics were run for the overall sample, and to test for differences at baseline 
between groups. Analyses for Aim 1 first assessed effectiveness of the protocol for the entire 
sample, regardless of group assignment using paired samples t-test or signed rank test if 
normality assumption was violated for all primary outcome variables. To test for differences 
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between groups, two-sample t-tests were run or the Wilcoxon rank-sum test was run if the 
normality assumption was not satisfied. To assess Aim 2, a bivariate correlation was run 
between change in % kilocalories obtained orally and change in pain on the NCCPC-R. As 
this is a pilot study, corrections for multiple comparisons were not included. The analyses of 
24 week pre-post change were based upon completers only. An a priori sample size 
calculation based upon the primary outcome variable of % kilocalories obtained orally 
(assuming a success rate in the amitriptyline group of 80%, and in the control group of 
30%), revealed that a one-sided Fisher exact test has 81% power of detecting the difference 
with 15 subjects in each group (total 30 patients).
RESULTS
A total of 21 patients were randomized and enrolled September 2010, through December 1, 
2014 (Table II and Figure 2; available at www.jpeds.com). Baseline characteristics are 
presented in Table III (available at www.jpeds.com). Twelve were assigned to placebo and 9 
to amitriptyline; 10 were female (52.63%) and 17 were white (80.95%). The two groups 
(placebo, amitriptyline) were not significantly different at baseline on any key 
characteristics. Two patients withdrew prior to the baseline visit (10%), and 5 more patients 
withdrew during the study (5 placebo, 2 amitriptyline; 24%) leaving 14 completers (7 
placebo, 7 amitriptyline). Reasons for withdrawal included: not completing baseline 
paperwork (n = 2); seizure (n = 1, assigned to placebo), parent disagreement regarding 
suitability of patient for protocol (n = 1), poor compliance with protocol (n = 1), and weight 
loss (n = 2).
All patients who completed the protocol (regardless of group assignment) obtained 100% of 
their kilocalories orally at post treatment (baseline % kilocalories oral = 26.93 ± 16.31; post 
= 100.00 ± 0.00); t = −16.16, p < .001). BMI percentile decreased across the entire sample 
from pre (45.11 ± 30.63) to post (27.86 ± 30.52; t = 2.73, p = .017). Pain decreased from pre 
(12.85 ± 12.37) to post (8.0 ± 14.27; t = 1.85, p = 0.006). Non-statistically significant 
changes from pre to post included decreases in total cost of care (in US dollars; pre = 643.54 
± 1495.98; post = 115.29 ± 149.19; z = 1.51; p = 0.13). Table IV (available at 
www.jpeds.com) shows quality of life changes. There were no between group (placebo/
amitriptyline) differences for change from pre to post-treatment for any of the measures 
(Table V).
Aim 2, the role of pain in the efficacy of the protocol (regardless of group assignment), was 
difficult to assess as all of the children who completed the study were taking all of their 
calories orally at the end of the study, meaning that there were ceiling effects in terms of 
protocol effectiveness. The correlation between change in % kilocalories obtained orally and 
change in total NCCPC-R score was not significant (Pearson correlation = −0.35, p = .27).
There were no Serious Adverse Events (SAEs) reported during the current study that were 
determined to be associated with the protocol. Reported symptoms that patients experienced 
during the study period included irritability, vomiting, choking, constipation, cough, Crohn’s 
disease exacerbation, elbow injury, fever, gum sensitivity/teething, infectious pneumonia, 
post-nasal drip, restless sleep, watery eyes, low cortisol levels. The low morning serum 
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cortisol levels were associated with the 6 weeks of megesterol. Based upon these findings in 
the initial subjects, we changed the protocol to include megesterol for only 4 weeks, rather 
than the planned 6 weeks, which avoided the adrenal hypofunction. There were no side 
effects or EKG changes associated with the amitriptyline. Details of the effects of 
amitriptyline on ECGs can be found in a separate publication.(22)
DISCUSSION
The current study assessed the efficacy of amitriptyline in a 24-week outpatient 
multidisciplinary protocol for transitioning infants and toddlers from tube to oral feeding. Of 
the 21 patients who were randomized, 2 did not complete baseline paperwork, and 5 more 
withdrew during the protocol. The rate of drop out after starting treatment (24%) is 
consistent with previous research of this nature (30%; 12). Of all patients enrolled in the 
study (including completers and noncompleters), 87.5% transitioned to oral feeding 
regardless of group assignment, demonstrating that amitriptyline was not necessary in 
transitioning children to oral eating. The only other study of an outpatient clinic based 
protocol for moving children off of their feeding tubes found a 47% success rate for their 
behavioral therapy intervention (and a 0% success rate for their nutritional intervention) 
(13). A study of weaning children through hunger provocation during a day-treatment 
program (23) attained an 86% success rate in the two-week program. Thus, the success rate 
of the current protocol appears to be an improvement over both clinic based programs and 
daytreatment programs.
The current study utilized an appetite stimulant, which could have contributed to the success 
of participants. The precise mechanism of action that leads to increased appetite and weight 
gain is unknown, but is likely related to megestrol’s glucocortocoid effect (24). There are 
several pediatric trials examining megesterol therapy for anorexia or malnutrition (25–27); 
however, safety and efficacy in children like those studied here remain to be defined. Studies 
of megestrol and other appetite stimulants used in the pediatric population are warranted, 
with a focus on their use in facilitating tube weaning.
Our primary measure of body mass, BMI percentile, decreased regardless of group 
assignment, but remained in the “normal” range. Hartdoff et al found a mean weight loss of 
8.8% in their hunger provocation day-treatment study, less than the rate of weight loss found 
here. Across both our study and the Hartdorff study, a few parents withdrew children due to 
parent concerns about weight loss. Unfortunately, neither study assessed for parent stress 
using a validated measure, which would help to further delineate the relationship between 
parent stress and tube weaning. Another possibility regarding the weight loss seen in 
children undergoing the transition from tube to oral feeding may be that tube fed children 
are actually overfed (28).
We hypothesized that pain plays an important role in feeding refusal in children (29), which 
is why we included a pain treatment medication (amitriptyline) and jejunal feedings in our 
protocol. The current results do not support amitriptyline as a key component, but it is 
possible that pain (or, parent perception of pain) may play a role. Pain, as measured by 
parent report, decreased from pre to post for the entire sample, with no differences by group, 
Davis et al. Page 6
J Pediatr. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and there was no relationship between change in % kilocalories oral and change in pain 
scores. All patients in our study received continuous overnight feedings for 10 weeks prior 
to the initiation of tube weaning. Continuous overnight feedings avoid the gastric distension 
associated with bolus feeding, which can be perceived as a noxious stimulus in a patient 
with visceral hypersensitivity. Lack of pediatric-specific literature comparing the use of 
continuous versus bolus feeds highlights the existence of a knowledge gap that, if studied, 
may help us to understand how pain may be related to weaning in tube fed children.
Baseline and post-study scores for quality of life were generally low (poor). Others reported 
children with functional abdominal pain and burns (30) had quality of life scores that were, 
on average, at least 10 points higher than the scores found in this tube feeding sample. Our 
data do suggest that tube feeding may negatively impact child quality of life, and that 
transitioning to oral feeding may improve child quality of life, but that it still may remain 
negatively impacted even after the transition to oral feeding. Thus, there may be a need for 
continued work with the family to improve quality of life even after the transition has taken 
place, which is not currently part of routine interdisciplinary clinical care.(31) The current 
results suggest that quality of life improves, as measured by some subscales, as a child 
transitions from tube to oral eating. The subscales of Growth & Development, Behavior, 
General Health Perceptions, Parental Impact: Emotional, and Parental Impact: Time 
improved significantly on the ITQOL from pre to post. Therefore, any work on quality of 
life after the transition to oral feeding may want to focus on Physical Abilities, Discomfort/
Pain, Temperament and Moods, and General Behavior as these were the subscales that did 
not see statistically significant improvements from pre to post treatment.
The average cost of care decreased as the child transitioned from tube feeding to oral 
feeding, but this change was not statistically significant due to the large variations in 
reported cost, regardless of group assignment. Future studies would overcome these 
weaknesses by using a larger sample size, or by using a more highly structured measure of 
cost, perhaps one that also asked if the previous 7 days was representative of the previous 
weeks or asked about a representative week, as possibly there was also variability on a week 
by week basis that was not captured by our current measure.
The current study had several weaknesses, primarily our small sample size. The small 
sample size was directly due to problems with recruitment, which occurred uniformly across 
the four participating sites. The primary reason for refusal was that parents did not want to 
be randomly assigned to the amitriptyline/placebo – they either wanted the drug or did not, 
but refused to leave that decision to chance. Despite the lack of ability to recruit our target, 
however, we did achieve statistically significant results for the effectiveness of our protocol, 
indicating that our power calculations may have overestimated our needs. It is also possible, 
however, that had we recruited a larger sample some of our secondary measures, such as 
cost, may have achieved statistically significant results. Further research with larger samples 
will be necessary to determine if and how amitriptyline may affect the relationship between 
pain and oral intake in these medically complicated children. Future research will also need 
to assess how our protocol works for specific age groups and developmental ranges, as these 
ranges for the current study were rather broad.
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In terms of future directions, we need a better understanding of which remaining parts of the 
protocol are key to successful weaning, particularly focusing on whether or not megesterol 
impacts the transition to oral feeding. Other important components of the protocol that need 
further investigation include the use of continuous jejunal feedings, the 10-day nature of the 
tube wean, and the impact of the amount of time a child has been tube fed on this weaning 
process. Outside of protocol efficacy, the results here have suggested a need for future 
research regarding whether or not tube fed children are overfed, and what role parent stress 
plays in the weaning process. For example, it may be possible that amitriptyline could be 
useful for specific groups of children, such as those from families where parent stress plays a 
very large role, or for children with a significant pain history.
In sum, the current study does not support amitriptyline as a component of our protocol for 
weaning children from tube to oral feeding. Future research, as outlined above, is needed in 
order to determine the optimal methods for moving medically fragile children from tube to 
oral feeding.
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Figure 1. 
Procedures Timeline.
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Figure 2. 
CONSORT diagram.
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Table 1
Oral-Motor and Behavioral Skills.
Name of Skill Descriptor
Age-appropriate strength and 
coordination of the oral cavity1
Adequate range of motion, strength and coordinated movement of the lips, tongue, jaw; if safety of 
swallow is in question, a study will be done to assess; child must have safe swallow to proceed
Head/Neck/Trunk support1 Strength and control of the head, neck, and trunk to provide midline stability of the body
Sensory processing1 No major overt sensory processing issues that interfere with daily life activities, specifically eating/
feeding
Regular meals1 Coming to the meal setting at least 2–3 times per day, willingly
Limited grazing2 Child does not simply graze throughout the day, but participates in structured family mealtimes
Same location1 Daily meals take place in the same location
Meal Length2 Meal length falls between 10–20 minutes
Meal distractions2 There are few distractions during mealtime (ex. TV), that occur on a routine basis; a child who 
requires significant distraction in order to take bites is not eligible
Family mealtime2 The child and family eat meals together on a regular basis
Structured start & end2 The parent dictates the start and end of the meal with a simple command such as “It’s time to eat” or 
“You may get down now”
Parent behavior during meals2 Parent behavior during meals is appropriate with limited coaxing and no yelling or threatening
Force feeding1 There is never any forcing of food or other objects into the child’s mouth
Meal demeanor1 Child is neutral or positive in response to mealtime without crying or constantly turning head away 
from spoon
Good food presentation2 Appropriate amount/variety of foods are presented in a calm, relaxed manner; feeders announce each 
bite
1
Required prior to starting protocol;
2
Trained during first 10 weeks of protocol if not present at baseline.
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Table 2
Pre-existing diagnoses at time of enrollment.1
Age Sex Diagnoses
3 F Spastic quadriplegia, strabismus
2 F Abnormal facies, hypotonia, developmental delay
4 M None2
4 F Cow milk protein allergy
2 M Abnormal facies, developmental delay
6 F Abnormal facies, low muscle mass, hypotonia, developmental delay
2 M Developmental delay, GERD,3 asthma, allergies
3 F Autosomal deletion syndrome, webbed toes, GERD, constipation
4 M Developmental delay, constipation
3 F Asthma
4 M Constipation, sinusitis, GERD
4 F Asthma, constipation
3 M Attention deficit hyperactivity disorder, GERD
3 F Respiratory failure (vent dependent), vomiting, constipation, asthma, GERD
7 F GERD, recurrent ear infections, developmental delay
3 M Developmental delay
4 F Crohn's disease, reactive airway disease, colostomy, scoliosis
4 M Constipation, seizure disorder, short stature, developmental delay, cerebral palsy, GERD
6 M Bronchopulmonary dysplasia, necrotizing enterocolitis, post fundoplication, vomiting, constipation, attention deficit hyperactivity 
disorder, patent ductus arteriosuspost ligation
4 M Reactive airway disease, GERD, hepatitis
1
For one patient who was consented, not enrolled, this information was not available, so they are not listed below.
2All patients had pre-existing diagnoses of feeding problems or failure to thrive prior to initiation of tube feedings.
3GERD = Gastro esophageal reflux disease.
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Table 3
Baseline demographics for total sample, and by group.
Total
Sample
Amitriptyline Placebo
N 21 9 12
Sex (% female) 52.63 44.44 60.00
Age M (SD) 3.73 (1.99) 3.54 (2.25) 3.89 (1.84)
% Caucasian 80.95 100.00 66.67
*No significant differences between groups.
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Table 4
Results of the Infant Toddler Quality of Life.
Subscale No.
of
Items
Baseline
M(SD)
Post
M(SD)
t
Physical Abilities 10 71.11 (30.95) 72.59 (17.19) −.280
Growth and development 10 61.25 (13.51) 70.83 (12.85)
−2.285*
Discomfort/pain 3 70.83 (26.71) 79.86 (16.07) −1.817
Temperament and moods 18 71.53 (11.28) 74.31 (13.26) −.665
General behavior 12 63.37 (14.50) 66.67 (17.04) −1.012
Behavior 15 62.22 (9.44) 69.31 (9.81)
−2.376*
General health perceptions 11 39.39 (13.41) 49.43 (20.42)
−2.717*
Parental impact: Emotional 7 63.09 (12.86) 70.24 (11.02)
−2.232*
Parental impact: Time 7 66.27 (22.47) 82.94 (20.55)
−3.718**
*Only multi-item scales were included in the current study.
*p< .05;
**p < .005.
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Table 5
Change scores from pre to post on key variables by group.
Amitriptyline Placebo
% kilocalories obtained orally 68.62 (17.29) 76.89 (15.68)
BMI percentile −25.06 (29.47) −9.44 (14.25)
NCCPC-R −2.5 (19.85) −6.86 (8.65)
ITQOL - Behavior −20.63 (38.25) −16.58 (42.53)
Cost of Care −61.67 (89.34) −994.83 (1884.78)
Note: differences not statistically significant.
J Pediatr. Author manuscript; available in PMC 2017 May 01.
